Eileen M Raynor1, Hannah L Martin1, Emily Poehlein2, Hui-Jie Lee2, Paul Lantos3. 1. Department of Head and Neck Surgery and Communication Sciences Duke University Durham North Carolina USA. 2. Department of Biostatistics and Bioinformatics Duke University Durham North Carolina USA. 3. Department of Pediatric Infectious Disease Duke University Durham North Carolina USA.
Abstract
Objectives/hypothesis: The objective of this study is to describe long-term hearing outcomes in infants born to mothers with a known cytomegalovirus (CMV) positivity who were not tested for congenital CMV. Study type: Clinical research study. Design: Retrospective cohort study. Methods: Retrospective chart review was performed for mothers seropositive to CMV. Mother-infant dyads (130) were identified between January 1, 2013 and January 1, 2017. Outcomes data was collected through June 1, 2020. Demographics, risk factors for hearing loss, evidence of CMV infection, other causes of hearing loss, need for speech therapy services, and results of all hearing tests were collected. Results: All 130 infants were asymptomatic and 5 were tested for congenital CMV. Five were negative for CMV and excluded from analyses. Of the remaining 125, only 1 had low-viral avidity IgG antibodies. None had IgM antibodies. Four children (3.2%) had hearing loss at last audiogram and one child had delayed onset SNHL due to an enlarged vestibular aqueduct. Speech therapy for communication was required for 33 children (26.4%). Conclusions: Knowledge of maternal perinatal CMV status can allow for education about possible sequelae of cCMV, as well as trigger an alert for testing babies born to mothers with low-viral avidity IgG during the first trimester, when the risk of vertical transmission is highest. Also, babies born to CMV positive mothers may be more at risk for communication delays necessitating intervention. Studies focusing on the impact of maternal CMV related to childhood communication deficits could elucidate any direct relationships.
Objectives/hypothesis: The objective of this study is to describe long-term hearing outcomes in infants born to mothers with a known cytomegalovirus (CMV) positivity who were not tested for congenital CMV. Study type: Clinical research study. Design: Retrospective cohort study. Methods: Retrospective chart review was performed for mothers seropositive to CMV. Mother-infant dyads (130) were identified between January 1, 2013 and January 1, 2017. Outcomes data was collected through June 1, 2020. Demographics, risk factors for hearing loss, evidence of CMV infection, other causes of hearing loss, need for speech therapy services, and results of all hearing tests were collected. Results: All 130 infants were asymptomatic and 5 were tested for congenital CMV. Five were negative for CMV and excluded from analyses. Of the remaining 125, only 1 had low-viral avidity IgG antibodies. None had IgM antibodies. Four children (3.2%) had hearing loss at last audiogram and one child had delayed onset SNHL due to an enlarged vestibular aqueduct. Speech therapy for communication was required for 33 children (26.4%). Conclusions: Knowledge of maternal perinatal CMV status can allow for education about possible sequelae of cCMV, as well as trigger an alert for testing babies born to mothers with low-viral avidity IgG during the first trimester, when the risk of vertical transmission is highest. Also, babies born to CMV positive mothers may be more at risk for communication delays necessitating intervention. Studies focusing on the impact of maternal CMV related to childhood communication deficits could elucidate any direct relationships.
Authors: Adriana S Lopez; Tatiana M Lanzieri; Angelika H Claussen; Sherry S Vinson; Marie R Turcich; Isabella R Iovino; Robert G Voigt; A Chantal Caviness; Jerry A Miller; W Daniel Williamson; Craig M Hales; Stephanie R Bialek; Gail Demmler-Harrison Journal: Pediatrics Date: 2017-11 Impact factor: 7.124
Authors: Sheila C Dollard; Maggie Dreon; Nelmary Hernandez-Alvarado; Minal M Amin; Phili Wong; Tatiana M Lanzieri; Erin A Osterholm; Abbey Sidebottom; Sondra Rosendahl; Mark T McCann; Mark R Schleiss Journal: JAMA Pediatr Date: 2021-03-01 Impact factor: 16.193